Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators

@article{Lnning2003ClinicalPO,
  title={Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators},
  author={P. L{\o}nning},
  journal={Clinical Pharmacokinetics},
  year={2003},
  volume={42},
  pages={619-631}
}
  • P. Lønning
  • Published 2003
  • Chemistry, Medicine
  • Clinical Pharmacokinetics
Novel Aromatase Inhibitors
Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
TLDR
This is the first study that has showcased BIM IX as a COVID-19 inhibitor thereby validating the pipeline and demonstrating the value of repurposing approved and investigational drugs/compounds. Expand
Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays
Yash Gupta Loyola University Chicago Stritch School of Medicine, Chicago, IL, 60153, USA & Department of Medicine, Loyola University Medical Center, Chicago, IL, 60153, USA Dawid Maciorowski LoyolaExpand
Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole
TLDR
Using nanofiltration membranes for recovery of phosphorous with a second type of technology for the recovery of nitrogen is suggest to be a viable process. Expand
The pharmacokinetics of letrozole in brain and brain tumor in rats with orthotopically implanted C6 glioma, assessed using intracerebral microdialysis
TLDR
Letrozole permeability across the blood brain barrier is high, and the exposure to the brain is dose dependent, which underscore potential selectivity of its activity against tumor cells. Expand
Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model.
TLDR
It is shown that genistein can induce estrogen-dependent MCF-7 tumor cell growth and increase breast cancer-associated aromatase expression and activity in vitro and suggest that soy-based supplements might affect the efficacy of breast cancer treatment with aromat enzyme inhibitors. Expand
Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Breast Cancer Treatment
TLDR
No treatment should commence before careful evaluation of the physiological reserve of an older individual has been assessed, while during treatment an ongoing routine must assure that in case of preceding under- or overestimation of the assumed biological age of a patient, it is recognized in an early phase and treatment is adjusted accordingly. Expand
Clinical pharmacology of aromatase inhibitors
TLDR
Understanding of the effects of these compounds at the tissue level, in particular with respect to local effects in the normal breast as well as breast tumour tissue, is still incomplete. Expand
Effectiveness of Anastrozole and Cyproterone Acetate in Two Brothers with Familial Male Precocious Puberty
TLDR
Combined treatment with anastrozole and cyproterone acetate is effective in improving the prognosis of adult height in testotoxicosis. Expand
...
1
2
...

References

SHOWING 1-10 OF 126 REFERENCES
A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer
TLDR
There is no indication that the increased toxicity seen with the addition of aminoglutethimide to tamoxifen in this situation is justified by an increased response rate. Expand
Arimidex®: A potent and selective fourth-generation aromatase inhibitor
TLDR
Arimidex® is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer and had no clinically significant effects on key enzymes that regulate cortisol and aldosterone biosynthesis. Expand
Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
TLDR
This study shows that potent aromatase inhibition with 4-OHA is effective in women with advanced BC who have already been treated with a less potent arom atase inhibitor, and suggests that relative changes in oestrogen levels may be more important than absolute levels. Expand
Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men
TLDR
An increase in androgen levels was observed that may have been due to competitive inhibition of enzymes involved in metabolic clearance of androgens and/or to decreased feedback inhibition of gonadotrophin secretion by oestradiol. Expand
Dose Proportionality and Population Characteristics of Oral Fadrozole Hydrochloride, an Aromatase Inhibitor, in Postmenopausal Women
TLDR
It was concluded that the pharmacokinetics of fadrozole were dose proportional in the projected therapeutic dose range and the relationship between oral clearance and the demographic factors, age, weight, and height, was assessed. Expand
High-performance liquid chromatographic assay for simultaneous estimation of aminoglutethimide and acethylamidoglutethimide in biological fluids
SummaryA simple rapid high-performance liquid chromatographic assay for simultaneous estimation of aminoglutethimide and its acetylated metabolite acetylamidoglutethimide in plasma, saliva, and urineExpand
Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer
TLDR
The results suggest that AG stimulates the metabolism of progestins, and reduces the biological activity of progESTins. Expand
Phase III Randomized Trial of Toremifene vs Tamoxifen in Hormonodependant Advanced Breast Cancer
TLDR
The data suggest that TOR is an efficient and well-tolerated agent for the therapy of postmenopausal women with hormonal positive receptorsAdvanced breast cancer, and must be considered an alternative to TAM as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment. Expand
The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients
TLDR
The findings are consistent with a hypothesis that 4OHA given orally may cause substantial plasma oestrogen suppression during part of the day, but neither the od nor the bd regimens investigated in the present study were capable of producing optimal aromatase inhibition. Expand
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
TLDR
Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer and longer follow-up is required before a final benefit:risk assessment can be made. Expand
...
1
2
3
4
5
...